Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24054627 | 0.84 | HTT (0.47) | HTTTDP1FGFR1KMT2ALMNA | |
| SCHEMBL1293053 | 0.83 | TDP1 (0.52) | HTTTDP1FGFR1KMT2ALMNA | |
| SCHEMBL3968932 | 0.79 | TDP1 (0.48) | HTTTDP1FGFR1KMT2ALMNA | |
| SCHEMBL30275503 | 0.79 | MEN1 (0.49) | HTTTDP1FGFR1KMT2ALMNA | |
| SCHEMBL28860663 | 0.79 | TDP1 (0.48) | HTTTDP1FGFR1KMT2ALMNA | |
| SCHEMBL15357737 | 0.79 | TDP1 (0.44) | HTTTDP1FGFR1KMT2ALMNA | |
| SCHEMBL4180919 | 0.78 | TDP1 (0.47) | HTTTDP1FGFR1KMT2ALMNA | |
| SCHEMBL9378031 | 0.77 | FGFR1 (0.50) | HTTFGFR1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL9529264 | 0.76 | TDP1 (0.46) | HTTTDP1FGFR1KMT2ALMNA | |
| SCHEMBL160156 | 0.76 | TDP1 (0.46) | HTTTDP1FGFR1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119019788-A | High-strength fire-resistant cable and preparation process thereof | 江苏东旭电缆有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-101437919-A | CMP method for copper-containing substrates | CABOT MICROELECTRONICS CORP (US) | 2009-05-20 | — | — | CN | claimed |
| EP-1105387-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2000009498-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) | 2000-02-24 | — | — | WO | claimed |
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-119019788-A | High-strength fire-resistant cable and preparation process thereof | 江苏东旭电缆有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119019369-A | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-115397821-B | Bifunctional molecules comprising an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety | 阿尔维纳斯运营股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118388454-A | Modulators of BCL6 proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| US-4873346-A | BRONCHODILATORS, TREATMENT OF ASTHMA | THE UPJOHN COMPANY (US) | 1989-10-10 | — | — | US | disclosed |
| US-4619997-A | Substituted 2-pyridylmethylthio and sulfinyl-benzimidazoles as gastric antisecretory agents | THE UPJOHN COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
| US-4575554-A | CYTOPROTECTIVE | THE UPJOHN COMPANY (US) | 1986-03-11 | — | — | US | disclosed |
| US-4463173-A | ANTIBIOTIC, BACTERICIDE | ICI PHARMA (FR) | 1984-07-31 | — | — | US | disclosed |
| EP-0031708-B1 | CEPHALOSPORIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES THEREFOR | ICI PHARMA (FR) | 1984-06-13 | — | — | EP | disclosed |
| EP-0048834-A1 | Method for measurement of trace enzymes | FUJI PHOTO FILM CO., LTD. (JP) | 1982-04-07 | — | — | EP | disclosed |
| EP-0047470-A1 | Method for immunochemical measurement | FUJI PHOTO FILM CO., LTD. (JP) | 1982-03-17 | — | — | EP | disclosed |
| EP-0031708-A2 | Cephalosporin derivatives, processes for their manufacture, pharmaceutical compositions containing them and intermediates therefor | ICI PHARMA (FR) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970480-B2 | Heterocyclic amides useful as protein modulators | RB1, RBBP5, RCC2 | HTT 876/4885TDP1 1654/4885FGFR1 2213/4885 |
| US-20250340535-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HTT 3411/4885TDP1 2058/4885FGFR1 164/4885 |
| US-12391671-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB2, ERBB3 | HTT 3411/4885TDP1 2058/4885FGFR1 164/4885 |
| US-20250340534-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | HTT 3411/4885TDP1 2058/4885FGFR1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.